« Dense bones linked to raised risk for prostate cancer | Home | Dense bones linked to raised risk for prostate cancer »

Dendreon’s Prostate Cancer Drug Extends Life in Published Study

By Yahoo! News Search Results for prostate cancer | July 28, 2010

Dendreon Corp.’s prostate cancer vaccine, Provenge, extended lives by 4.1 months in a study published in the New England Journal of Medicine. The data, released previously, led to the drug’s U.S. approval in April.

Topics: Uncategorized |

Comments